APA (7th ed.) Citation

X, L., C, H., J, L., A, B., A, P., L, K., . . . T, F. (2024). Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: The randomized phase 3 BENEFIT trial. Nature medicine, 30(8), 2235. https://doi.org/10.1038/s41591-024-03050-2

Chicago Style (17th ed.) Citation

X, Leleu, et al. "Isatuximab, Lenalidomide, Dexamethasone and Bortezomib in Transplant-ineligible Multiple Myeloma: The Randomized Phase 3 BENEFIT Trial." Nature Medicine 30, no. 8 (2024): 2235. https://doi.org/10.1038/s41591-024-03050-2.

MLA (9th ed.) Citation

X, Leleu, et al. "Isatuximab, Lenalidomide, Dexamethasone and Bortezomib in Transplant-ineligible Multiple Myeloma: The Randomized Phase 3 BENEFIT Trial." Nature Medicine, vol. 30, no. 8, 2024, p. 2235, https://doi.org/10.1038/s41591-024-03050-2.